The EMPEROR-PRESERVED trial findings corroborated the efficacy of SGLT2 inhibition towards HF with LVEF >40%, indicating a 29% reduction in HF hospitalizations associated with an improvement in patients’ quality of life, regardless of the presence of DM [156]. Here, SLC5A2 is linked to diabetes mellitus.